selected publications
- Treatment of sarcoidosis in US rheumatology practices: comment on the article by Hamman et al. Arthritis care & research. 2022 Letter GET IT
- Granulomatous disease and the two faces of Janus: divergent effects of tofacitinib therapy for inflammatory arthritis. Clinical and experimental rheumatology. 2021 Letter GET IT
-
When the Game Changes: Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 Pandemic.
Chest.
2020
Editorial Article
GET IT
Times cited: 35 -
Drugs for cognitive loss and dementia.
The Medical letter on drugs and therapeutics.
2017
Academic Article
GET IT
Times cited: 5 -
Pilot study of a multidisciplinary gout patient education and monitoring program.
Seminars in arthritis and rheumatism.
2016
Academic Article
GET IT
Times cited: 28 -
Sarcoidosis: Rheumatology perspective.
Best practice & research. Clinical rheumatology.
2016
Review
GET IT
Times cited: 15 -
Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies.
The Journal of allergy and clinical immunology.
2011
Letter
GET IT
Times cited: 51 -
The CY domain of the Fcgamma RIa alpha-chain (CD64) alters gamma-chain tyrosine-based signaling and phagocytosis.
The Journal of biological chemistry.
2002
Academic Article
GET IT
Times cited: 23 -
Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy.
2001
GET IT
Times cited: 217 -
Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2000
Academic Article
GET IT
Times cited: 150 -
Remission of juvenile rheumatoid arthritis after infection with parvovirus B19.
1999
GET IT
Times cited: 15 -
The cytoplasmic domain of human FcgammaRIa alters the functional properties of the FcgammaRI.gamma-chain receptor complex.
The Journal of biological chemistry.
1999
Academic Article
GET IT
Times cited: 32 -
Adventitial stripping: a digit saving procedure in refractory Raynaud's phenomenon.
1998
GET IT
Times cited: 53 -
Fc gammaRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus.
Arthritis and rheumatism.
1997
Academic Article
GET IT
Times cited: 58 -
Serum activity that confers acid lability to alpha-interferon in systemic lupus erythematosus: its association with disease activity and its independence from circulating alpha-interferon.
1990
GET IT
Times cited: 22 -
Interferon alpha associated with systemic lupus erythematosus is not intrinsically acid labile.
The Journal of experimental medicine.
1989
Academic Article
GET IT
Times cited: 18